دورية أكاديمية
Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis.
العنوان: | Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis. |
---|---|
المؤلفون: | Roy S; Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, India., Moulik S; Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, India., Roy M; Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, India., Ghosh MK; Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India., Chaudhuri SJ; Department of Microbiology, Sarat Chandra Chattopadhyay Government Medical College and Hospital, Howrah, India., Pandey DK; Kala-Azar Elimination Programme, World Health Organization Country Office, New Delhi, India., Jain S; Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland., Dagne DA; Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland., Chatterjee M; Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, India. |
المصدر: | The American journal of tropical medicine and hygiene [Am J Trop Med Hyg] 2024 Mar 05; Vol. 110 (4), pp. 656-662. Date of Electronic Publication: 2024 Mar 05 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: American Society of Tropical Medicine and Hygiene Country of Publication: United States NLM ID: 0370507 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1476-1645 (Electronic) Linking ISSN: 00029637 NLM ISO Abbreviation: Am J Trop Med Hyg Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Northbrook, IL : American Society of Tropical Medicine and Hygiene Original Publication: Baltimore. |
مواضيع طبية MeSH: | Leishmaniasis, Visceral*/parasitology , Leishmaniasis, Cutaneous*/parasitology , Leishmania* , Leishmania donovani*, Phosphorylcholine/*analogs & derivatives, Humans ; DNA |
مستخلص: | Post-kala-azar dermal leishmaniasis (PKDL), the dermal sequel to visceral leishmaniasis (VL), is characterized by hypopigmented macules (macular) and/or papules and nodules (polymorphic). Post-kala-azar dermal leishmaniasis plays a significant role in disease transmission, emphasizing the need for monitoring chemotherapeutic effectiveness. Accordingly, this study aimed to quantify the parasite burden in PKDL patients after treatment with miltefosine by a quantitative polymerase chain reaction (qPCR). A Leishmania kinetoplastid gene-targeted qPCR was undertaken using DNA from skin biopsy specimens of patients with PKDL at three time points, i.e., at disease presentation (week 0, n = 157, group 1), upon completion of treatment (week 12, n = 39, group 2), and at any time point 6 months after completion of treatment (week ≥36, n = 54, group 3). A cycle threshold (Ct) <30 was considered the cutoff for positivity, and load was quantified as the number of parasites/µg genomic DNA (gDNA); cure was considered when samples had a Ct >30. The parasite load at disease presentation (group 1) was 10,769 (1,339-80,441)/µg gDNA (median [interquartile range]). In groups 2 and 3, qPCR results were negative in 35/39 cases (89.7%) and 48/54 cases (88.8%), respectively. In the 10/93 (10.8%) qPCR-positive cases, the parasite burdens in groups 2 and 3 were 2,420 (1,205-5,661)/µg gDNA and 22,195 (5,524-100,106)/µg gDNA, respectively. Serial monitoring was undertaken in 45 randomly selected cases that had completed treatment; all cases in groups 2 or 3 had a Ct >30, indicating cure. Overall, qPCR confirmed an 89.2% cure (as 83/93 cases showed parasite clearance), and the persistent qPCR positivity was attributed to nonadherence to treatment or unresponsiveness to miltefosine and remains to be investigated. |
References: | J Clin Microbiol. 2021 Aug 18;59(9):e0013221. (PMID: 34160275) Trop Med Int Health. 2013 Jan;18(1):96-100. (PMID: 23136856) PLoS Negl Trop Dis. 2015 Oct 22;9(10):e0004093. (PMID: 26492039) Open Forum Infect Dis. 2018 Sep 15;5(10):ofy234. (PMID: 30320150) Clin Infect Dis. 2002 Sep 1;35(5):581-6. (PMID: 12173133) Am J Trop Med Hyg. 2011 May;84(5):688-91. (PMID: 21540376) Front Cell Infect Microbiol. 2021 Feb 22;11:623437. (PMID: 33692966) Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):34-41. (PMID: 33580944) J Infect Dis. 2020 Feb 3;221(4):608-617. (PMID: 31854451) PLoS Negl Trop Dis. 2023 Apr 19;17(4):e0011231. (PMID: 37075066) Int J Dermatol. 2008 Apr;47(4):414-6. (PMID: 18377613) Trends Parasitol. 2019 Aug;35(8):590-592. (PMID: 31266711) Trans R Soc Trop Med Hyg. 2001 Apr;95 Suppl 1:S59-76. (PMID: 11370251) PLoS Negl Trop Dis. 2019 Mar 11;13(3):e0007249. (PMID: 30856178) Clin Infect Dis. 2019 Jul 2;69(2):251-258. (PMID: 30357373) Exp Parasitol. 2013 Oct;135(2):397-406. (PMID: 23968687) PLoS Negl Trop Dis. 2020 Jul 2;14(7):e0008221. (PMID: 32614818) Biomed Pharmacother. 2018 Dec;108:1170-1180. (PMID: 30372818) Open Forum Infect Dis. 2023 May 02;10(5):ofad231. (PMID: 37234513) Med Hypotheses. 2006;66(5):993-9. (PMID: 16386855) Indian J Dermatol Venereol Leprol. 2023 Jan-Mar;89(2):298-300. (PMID: 36461804) Sci Rep. 2022 Oct 27;12(1):18069. (PMID: 36302782) Clin Infect Dis. 2017 Jul 1;65(1):150-153. (PMID: 28520851) Clin Infect Dis. 2018 Jan 18;66(3):404-410. (PMID: 29020350) N Engl J Med. 2010 Feb 11;362(6):504-12. (PMID: 20147716) PLoS One. 2018 Sep 7;13(9):e0203407. (PMID: 30192805) Am J Trop Med Hyg. 2015 Oct;93(4):767-9. (PMID: 26175030) Indian J Dermatol. 2020 Nov-Dec;65(6):465-472. (PMID: 33487701) |
معلومات مُعتمدة: | 001 International WHO_ World Health Organization |
المشرفين على المادة: | 53EY29W7EC (miltefosine) 9007-49-2 (DNA) 107-73-3 (Phosphorylcholine) |
تواريخ الأحداث: | Date Created: 20240305 Date Completed: 20240405 Latest Revision: 20240420 |
رمز التحديث: | 20240420 |
مُعرف محوري في PubMed: | PMC10993836 |
DOI: | 10.4269/ajtmh.23-0197 |
PMID: | 38442428 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1476-1645 |
---|---|
DOI: | 10.4269/ajtmh.23-0197 |